Core Viewpoint - Karolinska Development AB has successfully completed a rights issue of Series B shares, achieving approximately 57% subscription, and will change its name to KDventures AB, effective around 10 February 2026 [2][3][10]. Rights Issue Outcome - The rights issue was subscribed to approximately 57%, with 21% through subscription rights and 2% without [3][5]. - The company will receive approximately SEK 115.2 million before issue costs, with a portion subject to ISP approval [3][6]. - If ISP approval is not obtained, the proceeds will be approximately SEK 114.9 million [6]. Share Allotment and Capital Increase - The allotment of shares was resolved on 28 January 2026, with a portion subject to ISP approval if it exceeds 9.99% of total voting rights [4]. - Assuming ISP approval, share capital will increase by approximately SEK 3,841,666.64, raising the total from SEK 2,700,775.94 to SEK 6,542,442.58, resulting in a dilution effect of approximately 59% [8]. - If ISP approval is not granted, the increase will be approximately SEK 3,830,431.43, with a dilution effect of approximately 58.9% [9]. Company Name Change - The company will officially change its name to KDventures AB, with a new trading symbol and short name on Nasdaq Stockholm [10][18]. - The new website will be launched at www.kd-ventures.com [10]. Trading and Conversion - Trading in paid subscribed shares (BTA) will occur under the short name KDEV B until 12 February 2026, with conversion into shares expected around 16 February 2026 [12]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on breakthrough medical innovations and advancing them into commercial products [15][16]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases [17].

Core Viewpoint - Karolinska Development AB has announced additional guarantee commitments of approximately 20 MSEK in its ongoing rights issue, bringing the total to approximately 115.2 MSEK, which covers about 57% of the rights issue volume [2][3]. Group 1: Rights Issue Details - The rights issue was resolved by the Board of Directors on December 1, 2025, and approved by the extraordinary general meeting on January 8, 2026, with a subscription period running until January 27, 2026 [2]. - The total rights issue amount is approximately 202.6 MSEK before issue costs [2]. - The Intermediate Guarantee covers the interval from approximately 47% to 57% of the rights issue, amounting to approximately 115.2 MSEK [3]. Group 2: Guarantee Commitments - Previously agreed guarantee commitments have increased from approximately 95.2 MSEK to approximately 115.2 MSEK [3]. - The guarantee commitments are not secured through bank guarantees or similar arrangements [5]. - A cash guarantee fee of 13% or a fee of 15% in newly issued shares will be paid for the Intermediate Guarantee [4]. Group 3: Shareholder Implications - Investors acquiring a shareholding of 10% or more of the total votes in the Company must notify the Inspectorate of Strategic Products prior to the investment [6]. - Any guarantee commitments that require approval under the Swedish Screening of Foreign Direct Investments Act are conditional upon obtaining such approval [6][19]. Group 4: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing medical innovations [10]. - The company aims to build companies around leading scientists and management teams, co-funded by international investors [11]. - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases [12].

Core Viewpoint - Karolinska Development AB is conducting a rights issue of series B shares amounting to approximately SEK 202.6 million, which has been approved by the Board of Directors and the extraordinary general meeting [2]. Group 1: Rights Issue Details - The rights issue is set to raise approximately SEK 202.6 million before transaction costs, as resolved by the Board on December 1, 2025, and approved on January 8, 2026 [2]. - An information document has been prepared in accordance with the Prospectus Regulation, detailing the terms and conditions of the rights issue, which has been registered with the Swedish Financial Supervisory Authority [3]. - The timetable for the rights issue includes trading in subscription rights from January 13 to January 22, 2026, and a subscription period from January 13 to January 27, 2026 [4]. Group 2: Advisory and Legal Support - Redeye AB is acting as the financial adviser, while Cirio Advokatbyrå AB serves as the legal adviser for the rights issue [5]. Group 3: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [7]. - The company aims to create and grow companies that advance medical innovations into commercial products, benefiting patients and providing returns to shareholders [8]. - Karolinska Development has access to world-class medical innovations from leading universities and research institutes, aiming to build companies around top scientists supported by experienced management teams [9].

Core Viewpoint - Karolinska Development AB is convening an Extraordinary General Meeting (EGM) on January 8, 2026, to discuss significant amendments to the Articles of Association, including a proposed name change and a rights issue to increase share capital [1][19]. Group 1: EGM Participation - Shareholders can participate in the EGM in person, by postal voting, or through a proxy [2][4]. - To participate in person, shareholders must be registered by December 23, 2025, and notify the company by January 2, 2026 [3]. - Postal voting requires registration by the same date, with completed forms submitted by January 2, 2026 [5][6]. Group 2: Agenda Items - The agenda includes the election of a chairperson, approval of the voting list, and amendments to the Articles of Association [15]. - Proposed amendments include changing the company name to KDventures AB and altering the business objectives [13][14]. - The company aims to increase its share capital through a rights issue, proposing to raise up to SEK 6,751,939.85 by issuing up to 675,193,985 new shares [19][20]. Group 3: Rights Issue Details - Each existing share entitles shareholders to five subscription rights, with two rights needed to subscribe for one new share at a price of SEK 0.30 [20]. - The record date for determining eligible shareholders for the rights issue is January 9, 2026 [22]. - Subscription for shares will occur from January 13 to January 27, 2026, with the possibility of extending this period [23]. Group 4: Share Capital Amendments - The proposed amendments to share capital include increasing the minimum from SEK 1,750,000 to SEK 2,650,000 and the maximum from SEK 7,000,000 to SEK 10,600,000 [17]. - The number of shares will also increase from a minimum of 175,000,000 to 265,000,000 and from a maximum of 700,000,000 to 1,060,000,000 [17]. Group 5: Voting Requirements - Resolutions regarding the amendments require support from shareholders representing at least two-thirds of the votes cast and shares represented at the EGM [28].

Core Viewpoint - Karolinska Development AB plans to conduct a rights issue of class B shares to raise approximately SEK 202.6 million for the continued development of existing investments, new investments, and general corporate purposes [2][4]. Rights Issue Details - The rights issue will consist of up to 675,193,985 new class B shares at a subscription price of SEK 0.30 per share, with an estimated transaction cost of SEK 16.8 million [4][9]. - Shareholders will have preferential rights, where one existing share grants five subscription rights, and two subscription rights allow for the purchase of one new class B share [4][9]. - The subscription period is from January 13, 2026, to January 27, 2026, with trading in subscription rights occurring from January 13 to January 22, 2026 [10][11]. Financial Commitments - Existing shareholders and members of the Board have committed approximately SEK 5.2 million, representing about 2.6% of the rights issue, while guarantee commitments total approximately SEK 95.2 million, or about 47% of the rights issue [3][12][13]. - The net proceeds will primarily be allocated to existing portfolio companies (approximately 75%) and general corporate purposes (approximately 25%) [10][8]. Company Background - Karolinska Development is an investment company focused on medical innovations with significant commercial potential, managing a portfolio of eleven companies, nine of which have drug candidates in clinical trials [6][7]. - The company aims to leverage its management expertise and co-investments with other investors to enhance the development and commercialization of its portfolio [7][23]. Extraordinary General Meeting - The rights issue is subject to approval by an Extraordinary General Meeting scheduled for January 8, 2026, which will also consider amendments to the company's articles of association and a proposed name change to KDventures AB [19][20].

Core Viewpoint - Ørsted, the world's largest offshore wind developer, will reduce its workforce by 2,000 positions by 2027, representing a quarter of its current roles, in response to various challenges and to enhance competitiveness in Europe [1][2]. Group 1: Workforce Reduction - Ørsted plans to cut approximately 2,000 jobs by the end of 2027 as part of its strategic focus on Europe and to improve competitiveness [1]. - The decision to reduce the workforce is linked to the completion of its large construction portfolio in the coming years, necessitating fewer employees [2]. Group 2: Financial Measures - Ørsted recently completed a rights issue, raising $9.35 billion (59.56 billion Danish crowns) from existing shareholders to address immediate financing needs and strengthen its capital structure [4][5]. - The rights issue was heavily discounted, priced at 66.60 crowns ($1.04) per share, compared to a closing price of 122.35 crowns ($19.18) [5]. Group 3: Industry Challenges - The offshore wind industry has faced significant challenges, including regulatory changes, cost inflation, and high interest rates, which have negatively impacted project economics [4]. - Ørsted has encountered difficulties in the U.S. market, particularly due to regulatory obstacles under the Trump Administration affecting offshore wind projects [3].

Company Actions - Orsted 的第三大股东计划参与该风力能源开发商的配股发行 [1]

Financial Strategy - Orsted 计划发行 94 亿美元（$9.4 billion）的股票[1] Project Funding - 该融资用于海上风电项目[1]

Core Viewpoint - Modus Therapeutics is conducting a fully secured rights issue to raise SEK 28.3 million for the continued development of its drug candidate sevuparin, aimed at treating chronic kidney disease with anemia [1][2][3]. Group 1: Rights Issue Details - The rights issue will provide SEK 28.3 million before issue costs, subject to approval at an extraordinary general meeting on July 29, 2025 [2][3]. - Major shareholders, including Karolinska Development, have committed SEK 17.7 million, covering 62.7% of the rights issue, with the remaining 37.3% underwritten by external parties [4]. Group 2: Purpose and Impact - The funds from the rights issue will be used to complete the ongoing clinical phase II study of sevuparin and to finance operations through the end of 2026 [3]. - The successful securing of the rights issue is viewed as a strong indicator of Modus Therapeutics' clinical strategy and financial health [5]. Group 3: Company Background - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [6][7]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [8].